Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Colleague Insights
Grand Rounds
Conferences
Video Expert Opinion
Living Resources
Sign in
Join now
story of the week
Published in Obesity, Metabolic Syndrome, and Prediabetes and
2 other channels

Journal Scan / Research · April 08, 2019

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

Circulation

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

James Januzzi MD

Circulation
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Circulation 2019 Mar 18;[EPub Ahead of Print], ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, J Kuder, SA Murphy, DL Bhatt, LA Leiter, DK McGuire, JPH Wilding, MP Bonaca, CT Ruff, AS Desai, S Goto, PA Johansson, I Gause-Nilsson, P Johanson, AM Langkilde, I Raz, MS Sabatine, SD Wiviott

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated